Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature

BACKGROUND: HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1–4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC. CASE PRESENTATION: We presented a case of a 68-year-old nonsmok...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Huanhuan, Liang, Qi, Xu, Xian, Tan, Shanyue, Wang, Sumeng, Liu, Yiqian, Liu, Lingxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600784/
https://www.ncbi.nlm.nih.gov/pubmed/34794435
http://dx.doi.org/10.1186/s12957-021-02444-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600784/
https://www.ncbi.nlm.nih.gov/pubmed/34794435
http://dx.doi.org/10.1186/s12957-021-02444-7

Ejemplares similares